Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes - Wikidata - awgldk - TriplyDB

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

http://www.wikidata.org/entity/Q28752503

about

sameAs

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals Structural Model of the Extracellular Assembly of the TCR-CD3 Complex.Conserved structural elements in the V3 crown of HIV-1 gp120 Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals Thermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120 Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India Isolation of monoclonal antibodies with predetermined conformational epitope specificity HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Statistical approaches to analyzing HIV-1 neutralizing antibody assay data HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

P2860

Q24635002-BF42DF19-F694-4877-B204-5BCA21476B01 Q27319571-DE35C63B-B443-438E-8471-2A786DEE21E5 Q27663325-B1E07A9F-54D5-4047-A618-3D1424FD0B58 Q27665884-A25DB960-E020-4262-A1E2-048C0B49754B Q27674878-46AD1CEC-AFE7-400B-BA0E-3BCAD69E3887 Q27676155-575DD94F-B9FC-444D-8D52-B1B3FD733545 Q27677941-8B279C2C-7972-47BF-A0F0-C828FF78581D Q27679559-6ABBD4A0-37B5-44B2-B477-2625217DFD33 Q28477253-A33584E1-F703-4D04-8A42-4816983A08D0 Q28483205-D9583D38-A260-4886-9CAE-5F105EA569C4 Q28728170-38F391F4-C016-42E9-9162-A85924CF3DED Q30355260-FC969B4B-D823-470B-99BC-99C143454FBD Q30603475-62B9BEA1-92B8-4E64-9210-4CCB4D714A37 Q30784057-EFCE26E6-7B64-40D7-8F75-806FFE89C4E9 Q30828739-1C3234C4-A032-4E5F-B3A1-B1B5126B42F2 Q30994182-4F821FD1-0128-4C42-988E-EA0368F390A2 Q33786140-5470CD65-25CB-4DA3-9350-446D390032FC Q33867353-80058FE1-D4A1-48FC-97DE-B12CD3139E9B Q34017550-122D2127-8987-4957-BEBA-74C2D7407CEB Q34023249-4F17CA53-D3FD-49AB-955F-135DC8D8DD70 Q34128200-9EDA858C-0A32-4B0C-B6EE-6426307869AD Q34164923-626DFCDF-9E8F-4F97-8756-75F49FEB0C5C Q34204047-3DA06CC9-29D6-4E47-91F5-22097672BB1E Q34225659-BF843316-6882-4244-891F-225B7E645391 Q34326222-82D39132-21C1-498E-A345-B20B434AF0D7 Q34374835-567BE909-967B-4450-8BE7-B8F6E359AFFB Q34402934-03A3E1B3-EE35-49FB-AFF4-F096C9B76EB7 Q34463861-B0145FBB-B6A1-4925-B4B7-9F7D84172F58 Q34499013-E482D3D0-76E1-4172-8599-292807D49C23 Q34533041-F70CF468-F569-4774-9E86-0FB25874CB07 Q34562259-FF555597-1CB2-4971-9641-C222784991B5 Q34847834-0ADCF10C-D11C-4ECF-AAC1-5D2FCD0D071D Q34948847-0FEC36FD-AFCE-4245-B193-5742574705E9 Q35076987-25E5D794-A99E-4968-8E22-A7D152FF6F89 Q35108505-B53B8167-E118-42AB-BD4C-CC92CC97CBF6 Q35161426-10C7A2CE-476B-4326-8444-9B68178EBCC6 Q35196671-D630FC21-F8D8-49EA-B6A8-7385ACAC0492 Q35298899-2B7F08EF-85DB-45E4-BA83-954429CA59DA Q35651494-0C8F47EA-61F3-445F-A35E-719CE1319030 Q35706462-C9A9DCF9-8CAA-421F-802B-AF42D5C2ED7B

P2860

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

http://www.wikidata.org/entity/Q28752503

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@ast

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@en

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@nl

type

label

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@ast

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@en

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@nl

prefLabel

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@ast

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@en

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@nl

P1433

Q28752503-43EF5C57-9188-4861-9B20-17A2735E73FB

P1476

Q28752503-3E33E4D4-9092-44A4-9C93-A9B6FE6D2800

P2093

Q28752503-247DF628-2352-459B-99FD-0E88FC9F32B4

Q28752503-321B3BB6-5C15-44BB-9841-59BB9E488C1C

Q28752503-39985473-A2DE-484D-A965-7AFC46BE9E20

Q28752503-5518B839-A46B-4097-ADFE-4942B3F61389

Q28752503-5882F6C8-E523-4868-83BD-77C6B7407AA5

Q28752503-CDA9D3DD-A66E-4024-A271-E5D493D26178

Q28752503-EC4AC7A3-ED48-4B1F-A623-D87EDF7C7ED7

Q28752503-F0651B73-98A8-4D88-89FA-6AD2C72F8174

P2860

Q28752503-015C5936-317E-4472-BDFA-398D0BB02987

Q28752503-0E475D61-E846-4389-AC1C-33410C6FDD70

Q28752503-0EAE655D-6D5D-45A8-94EC-02570CFB909A

Q28752503-15425921-5738-4238-8DAE-026224C96652

Q28752503-16E002CD-8D4F-427F-BC83-799C257CDDDE

Q28752503-1B60165D-D48D-43ED-997E-1C5F91AB3DB4

Q28752503-1CE802BF-04D4-4CE2-83CD-85C014D3B85C

Q28752503-1D11D455-896E-4285-8E04-E0371AB4D9B8

Q28752503-1D8A6DD0-6A10-4457-8F57-1C93BECDB051

Q28752503-240CFF33-71A1-41E3-811C-96E5E77BA601

P304

Q28752503-5236B436-805A-4C25-9DCA-6EB3DB2C405D

P31

Q28752503-76276B85-6245-4770-A85A-A327BBAE974B

P356

Q28752503-B2B1D334-3C99-478D-9CF6-D712DEDE23EB

P407

Q28752503-8B851346-F4E6-4B33-89C4-FECCC49655A2

P433

Q28752503-35751D99-C72A-4584-B0EE-2102D91B4A33

P478

Q28752503-DFBF2CE0-924F-4992-B440-73AF710E40B4

P50

Q28752503-81D3E48E-CBAD-479F-9B24-0B89029B0B54

P577

Q28752503-BA80D4A9-7813-403A-8D65-4524F2680E3A

P5875

Q28752503-88DC13B8-DC27-4166-ABAB-EE571C2BE062

P698

Q28752503-B664C456-1594-4485-B2D7-403A3B9E00E1

P921

Q28752503-723D7C06-B0B9-4666-A28A-6991BBBBC6F3

P932

Q28752503-C24B179D-5462-4D80-9E70-5E41E0826553

P356

JOURNAL.PONE.0010254

P1433

P1476

Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes

@en

P2093

Blake Wood

http://www.w3.org/2001/XMLSchema#string

Catarina E Hioe

http://www.w3.org/2001/XMLSchema#string

Constance Williams

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Steve Self

http://www.w3.org/2001/XMLSchema#string

Susan Zolla-Pazner

http://www.w3.org/2001/XMLSchema#string

Terri Wrin

http://www.w3.org/2001/XMLSchema#string

Xuesong Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization

Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens

GP120: target for neutralizing HIV-1 antibodies

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

P304

e10254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010254

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Miroslaw K Gorny

P577

2010-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43346189

http://www.w3.org/2001/XMLSchema#string

P698

20421997

http://www.w3.org/2001/XMLSchema#string

P921

P932

2858080

http://www.w3.org/2001/XMLSchema#string